Aldeyra Therapeutics, Inc to Post Q1 2023 Earnings of ($0.34) Per Share, SVB Leerink Forecasts (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) – Stock analysts at SVB Leerink issued their Q1 2023 EPS estimates for shares of Aldeyra Therapeutics in a note issued to investors on Thursday, March 9th. SVB Leerink analyst M. Goodman anticipates that the biotechnology company will post earnings per share of ($0.34) for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($1.38) per share. SVB Leerink also issued estimates for Aldeyra Therapeutics’ Q2 2023 earnings at ($0.33) EPS, Q3 2023 earnings at ($0.32) EPS, Q4 2023 earnings at ($0.26) EPS, FY2025 earnings at $0.90 EPS and FY2026 earnings at $2.35 EPS.

Several other analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, March 1st. StockNews.com upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, November 14th. Finally, Citigroup boosted their target price on shares of Aldeyra Therapeutics from $23.00 to $28.00 in a research note on Friday.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX opened at $7.18 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83. The firm has a market capitalization of $420.46 million, a price-to-earnings ratio of -6.77 and a beta of 1.07. The company’s fifty day moving average is $6.65 and its two-hundred day moving average is $6.17. Aldeyra Therapeutics has a 52-week low of $2.36 and a 52-week high of $8.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALDX. Knoll Capital Management LLC raised its position in Aldeyra Therapeutics by 24.9% during the third quarter. Knoll Capital Management LLC now owns 1,877,305 shares of the biotechnology company’s stock worth $10,025,000 after acquiring an additional 374,845 shares in the last quarter. Woodstock Corp increased its position in Aldeyra Therapeutics by 23.3% during the third quarter. Woodstock Corp now owns 129,179 shares of the biotechnology company’s stock worth $690,000 after acquiring an additional 24,445 shares during the period. Virtu Financial LLC bought a new position in Aldeyra Therapeutics during the third quarter worth about $99,000. International Assets Investment Management LLC grew its stake in Aldeyra Therapeutics by 4.8% during the second quarter. International Assets Investment Management LLC now owns 59,875 shares of the biotechnology company’s stock worth $239,000 after buying an additional 2,750 shares in the last quarter. Finally, Jump Financial LLC bought a new position in Aldeyra Therapeutics in the 3rd quarter valued at approximately $267,000. Institutional investors and hedge funds own 63.11% of the company’s stock.

About Aldeyra Therapeutics

(Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.